EntreMed, Inc. has initiated a Phase II trial to evaluate the safety and efficacy of its lead clinical-stage drug candidate, Panzem NCD, in combination with Avastin in patients with locally advanced or metastatic carcinoid tumors. The study will be coordinated by Boston’s Dana-Farber/Partners Cancer Care (DFPCC), a collaboration among The Brigham and Women’s Hospital, Inc., Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Beth Israel Deaconess Medical Center (BID...